Currently out of the existing stock ratings of Jami Rubin, 43 are a BUY (55.84%), 22 are a HOLD (28.57%), 12 are a SELL (15.58%).

Jami Rubin

Work Performance Price Targets & Ratings Chart

Analyst Jami Rubin, currently employed at GOLDMAN SACHS, carries an average stock price target met ratio of 78.43% that have a potential upside of 40.02% achieved within 788 days. Previously, Jami Rubin worked at MORGAN STANLEY.

Jami Rubin’s has documented 152 price targets and ratings displayed on 14 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on TEVA, Teva Pharma Industries Ltd ADR at 01-Oct-2018.

Wall Street Analyst Jami Rubin

Analyst best performing recommendations are on TEVA (TEVA PHARMA INDUSTRIES LTD ADR).
The best stock recommendation documented was for TEVA (TEVA PHARMA INDUSTRIES LTD ADR) at 12/15/2017. The price target of $20 was fulfilled within 26 days with a profit of $1.39 (7.47%) receiving and performance score of 2.87.

Average potential price target upside

of $46.6 (82.77%) on ABBV (ABBVIE).
of $27.8 (32.46%) on JNJ (JOHNSON & JOHNSON).
of $24.48 (20.74%) on ALNY (ALNYLAM PHARMACEUTICALS).

ABBV AbbVie AGN Allergan plc BMY Bristol-Myers Squibb Company JNJ Johnson & Johnson MRK Merck mpany MYL Viatris PRGO Perrigo Company PLC TEVA Teva Pharma Industries Ltd ADR LLY Eli Lilly and Company PFE Pfizer VTRS Viatris ALNY Alnylam Pharmaceuticals ZTS Zoetis ACT Enact Holdings

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Trung Huynh (RBC)